Dublin, July 16, 2019 (GLOBE NEWSWIRE) -- The "Aurora-GT" report has been added to ResearchAndMarkets.com's offering.

United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells), which is intended to rebuild blood vessels in the lung. Administering this gene therapy involves isolating a PAH patient's autologous endothelial progenitor cells, transfecting the cells with the gene for human endothelial NO-synthase, prior to their ex-vivo expansion, and reintroducing them into the same patient.

Analyst Outlook

United Therapeutics is aiming to diversify its pulmonary hypertension (PH) portfolio with a pipeline gene therapy product, Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells). The company stands out as the only one with a late-phase gene therapy in development. If successful, this therapy could address critical unmet need in the PH market for options beyond symptomatic treatment. The author awaits further developments for Aurora-GT, as Phase II/III clinical trial data are yet to be released.

Key Topics Covered:

OVERVIEW

• Drug Overview
• Product Profiles
• Aurora-GT : Pulmonary hypertension

LIST OF FIGURES
Figure 1: Aurora-GT for pulmonary hypertension - SWOT analysis

LIST OF TABLES
Table 1: Aurora-GT drug profile
Table 2: Aurora-GT Phase II trial in pulmonary hypertension

For more information about this report visit https://www.researchandmarkets.com/r/gcn35j

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.